Skip to content
value.today

Emergo Therapeutics, Inc.

🇺🇸 Durham, North Carolina, USAPharmaceuticalsFounded 2016
Total raised
$16 M
2 rounds on record
Latest round
$4 M
Oct 2020
First round on record
May 2018
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Emergo Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2020$4 MNo. 2$2 to $10 million

Emergo Therapeutics, Inc.: Raise no. 2, Oct 2020

Investors in this round

77 investors had bought by the notice of Oct 13, 2020: 77 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $5 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Moise Khayrallah · Executive Officer, Director
  • John E. Bailey, Jr. · Director
  • Margaret E. Powell · Director
  • Robert E. Helmedag · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Proceeds will be used for working capital, which may include normal compensation to executive officers.”

Signed by Moise Khayrallah, Ceo. Newest notice filed Oct 13, 2020. Read the notice at the SEC.

equitySEC
May 2018$12 MNo. 1$10 to $50 million

Emergo Therapeutics, Inc.: Raise no. 1, May 2018

Investors in this round

110 investors had bought by the notice of Sep 19, 2019: 110 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$12 M of $12 M offered
Smallest investment taken
$10,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Moise Khayrallah · Executive Officer, Director
  • Robin Hyde-DeRuyscher · Executive Officer
  • John E. Bailey, Jr. · Director
  • Margaret E. Powell · Director
  • Robert E. Helmedag · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Proceeds will be used for working capital, which may include normal compensation to executive officers.”

Signed by Moise Khayrallah, Ceo. Newest notice filed Sep 19, 2019. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Emergo Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2020).

    SEC Form D · Oct 2020

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Oct 2020

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Emergo Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Emergo Therapeutics, Inc.
NameRoleNamed in
Moise KhayrallahExecutive officerOct 2020
Robin Hyde-DeRuyscherExecutive officerSep 2019
John E. Bailey, Jr.DirectorOct 2020
Margaret E. PowellDirectorOct 2020
Moise KhayrallahDirectorOct 2020
Robert E. HelmedagDirectorOct 2020